hypertriglyceridemia Type Diabetes Mellitus,Metabolic Syndrome
Conditions
Interventions
None listed
Sponsors
Yasu Takanori
Eligibility
Inclusion criteria
Inclusion criteria: Patients who are currently attending or scheduled to attend outpatient clinics at Dokkyo Medical University Nikko Medical Center. Patients who are 18 years or older at the time of consent. Patients who have had fasting triglycerides of 150 mg/dl or higher, or random triglycerides of 175 mg/dl or higher at least once between 24 weeks before and at the time of consent, and have started standard treatment with SPPARM or fibrate drugs. Patients who have provided written consent to participate in the study.
Exclusion criteria
Exclusion criteria: Individuals who have previously taken SPPARM or fibrate drugs and experienced moderate or severe side effects. Individuals who are unable to make decisions on their own due to dementia or other conditions. Individuals deemed unsuitable for participation in the study by the principal investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the baseline values of capillary arterial blood flow velocity at rest and during reactive hyperemia, which are fingertip microcirculation parameters, from the start of standard treatment with SPPARM or fibrate drugs to 12 weeks later. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes or change rates from baseline to 12 weeks later in fingertip microcirculation parameters (vascular density and diameter at rest and during reactive hyperemia), fibrinogen, triglycerides, BAP, d-ROM, FFA, RLP-C, and blood fluidity. | — |
Contacts
Public ContactKeiko Yoshizawa
Dokkyo Medical University Nikko Medical Center
Outcome results
None listed